TTF

Molecular Alterations Associated With Improved Outcome in Patients With Glioblastoma Treated With Tumor-Treating Fields Bookmark

Do molecular biomarkers have any role in treating glioblastoma (GBM)? As outlined in this scientific research report from the academic journal Neuro-Oncology Research Advances, a recent study found that 3 biomarkers were correlated with very great outcome differences for people treated with tumor-treating (electrical) fields.

.

.

Global Post-Marketing Safety Surveillance of Tumor Treating Fields (TTFields) in Patients With High-Grade Glioma in Clinical Practice Bookmark

Research paper from the Journal of Neuro-Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

Safety and potential adverse effects are serious issues with many cancer treatments. This academic paper outlines post-marketing research that reveals few adverse effects from a type of treatment known as tumor-treating fields (TTF) in brain malignancies.

Go to full paper published in the Journal of Neuro-Oncology.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

A Systematic Review of Tumor Treating Fields Therapy for High-Grade Gliomas Bookmark

Research paper from Journal of Neuro-Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

Tumor-treating fields (TTF) is a type of cancer treatment that uses alternating electric pulses. Its use for adults with high-grade gliomas remains controversial, and as outlined in this academic review paper, more high-quality research is needed.

Go to full paper published in Journal of Neuro-Oncology.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.